Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market growth is projected to reach USD $ Billion in 2025, at a $% CAGR by driving industry size, share, segments research, top company analysis, trends and forecast report 2025 to 2031.

Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends and Outlook 2025-31

The global Monoclonal Antibodies for Non-small Cell Lung Cancer market size is predicted to grow from US$ 12710 million in 2025 to US$ 24580 million in 2031; it is expected to grow at a CAGR of 11.6% from 2025 to 2031. Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the bodys immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival. United States market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Monoclonal Antibodies for Non-small Cell Lung Cancer players cover Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the ?Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Forecast? looks at past sales and reviews total world Monoclonal Antibodies for Non-small Cell Lung Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibodies for Non-small Cell Lung Cancer sales for 2025 through 2031. With Monoclonal Antibodies for Non-small Cell Lung Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibodies for Non-small Cell Lung Cancer industry. This Insight Report provides a comprehensive analysis of the global Monoclonal Antibodies for Non-small Cell Lung Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibodies for Non-small Cell Lung Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibodies for Non-small Cell Lung Cancer market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibodies for Non-small Cell Lung Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibodies for Non-small Cell Lung Cancer. This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibodies for Non-small Cell Lung Cancer market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; 5 mg/mL &nbsp;&nbsp;&nbsp; 10 mg/mL &nbsp;&nbsp;&nbsp; 25 mg/mL &nbsp;&nbsp;&nbsp; 50 mg/mL Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Roche Holding AG &nbsp;&nbsp;&nbsp; Bristol Myers Squibb Co. &nbsp;&nbsp;&nbsp; Elea Spa &nbsp;&nbsp;&nbsp; Eli Lilly & Co. &nbsp;&nbsp;&nbsp; Merck & Co., Inc. &nbsp;&nbsp;&nbsp; AstraZeneca PLC &nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Henlius Biopharma Co., Ltd &nbsp;&nbsp;&nbsp; Jiangsu Hengrui Medicine Co., Ltd &nbsp;&nbsp;&nbsp; Innovent Biologics Co., Ltd &nbsp;&nbsp;&nbsp; Junshi Biosciences Co., Ltd &nbsp;&nbsp;&nbsp; BeiGene, Ltd &nbsp;&nbsp;&nbsp; Akeso, Inc Key Questions Addressed in this Report What is the 10-year outlook for the global Monoclonal Antibodies for Non-small Cell Lung Cancer market? What factors are driving Monoclonal Antibodies for Non-small Cell Lung Cancer market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Monoclonal Antibodies for Non-small Cell Lung Cancer market opportunities vary by end market size? How does Monoclonal Antibodies for Non-small Cell Lung Cancer break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Type &nbsp;2.2.1 5 mg/mL &nbsp;2.2.2 10 mg/mL &nbsp;2.2.3 25 mg/mL &nbsp;2.2.4 50 mg/mL &nbsp;2.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type &nbsp;2.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Type (2020-2025) &nbsp;2.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinic &nbsp;2.4.3 Others &nbsp;2.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application &nbsp;2.5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Breakdown Data by Company &nbsp;3.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company (2020-2025) &nbsp;3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Company &nbsp;3.4 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Product Location Distribution &nbsp;3.4.2 Players Monoclonal Antibodies for Non-small Cell Lung Cancer Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Monoclonal Antibodies for Non-small Cell Lung Cancer by Geographic Region &nbsp;4.1 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth &nbsp;4.4 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth &nbsp;4.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth &nbsp;4.6 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth 5 Americas &nbsp;5.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country &nbsp;5.1.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) &nbsp;5.1.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) &nbsp;5.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025) &nbsp;5.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region &nbsp;6.1.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) &nbsp;6.1.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) &nbsp;6.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025) &nbsp;6.3 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer by Country &nbsp;7.1.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) &nbsp;7.1.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) &nbsp;7.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025) &nbsp;7.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer by Country &nbsp;8.1.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer &nbsp;10.3 Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer &nbsp;10.4 Industry Chain Structure of Monoclonal Antibodies for Non-small Cell Lung Cancer 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors &nbsp;11.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer 12 World Forecast Review for Monoclonal Antibodies for Non-small Cell Lung Cancer by Geographic Region &nbsp;12.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Forecast by Region &nbsp;12.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Region (2026-2031) &nbsp;12.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Type (2026-2031) &nbsp;12.7 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Roche Holding AG &nbsp;13.1.1 Roche Holding AG Company Information &nbsp;13.1.2 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Roche Holding AG Main Business Overview &nbsp;13.1.5 Roche Holding AG Latest Developments &nbsp;13.2 Bristol Myers Squibb Co. &nbsp;13.2.1 Bristol Myers Squibb Co. Company Information &nbsp;13.2.2 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Bristol Myers Squibb Co. Main Business Overview &nbsp;13.2.5 Bristol Myers Squibb Co. Latest Developments &nbsp;13.3 Elea Spa &nbsp;13.3.1 Elea Spa Company Information &nbsp;13.3.2 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Elea Spa Main Business Overview &nbsp;13.3.5 Elea Spa Latest Developments &nbsp;13.4 Eli Lilly & Co. &nbsp;13.4.1 Eli Lilly & Co. Company Information &nbsp;13.4.2 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Eli Lilly & Co. Main Business Overview &nbsp;13.4.5 Eli Lilly & Co. Latest Developments &nbsp;13.5 Merck & Co., Inc. &nbsp;13.5.1 Merck & Co., Inc. Company Information &nbsp;13.5.2 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Merck & Co., Inc. Main Business Overview &nbsp;13.5.5 Merck & Co., Inc. Latest Developments &nbsp;13.6 AstraZeneca PLC &nbsp;13.6.1 AstraZeneca PLC Company Information &nbsp;13.6.2 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 AstraZeneca PLC Main Business Overview &nbsp;13.6.5 AstraZeneca PLC Latest Developments &nbsp;13.7 Regeneron Pharmaceuticals, Inc. &nbsp;13.7.1 Regeneron Pharmaceuticals, Inc. Company Information &nbsp;13.7.2 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Regeneron Pharmaceuticals, Inc. Main Business Overview &nbsp;13.7.5 Regeneron Pharmaceuticals, Inc. Latest Developments &nbsp;13.8 Henlius Biopharma Co., Ltd &nbsp;13.8.1 Henlius Biopharma Co., Ltd Company Information &nbsp;13.8.2 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Henlius Biopharma Co., Ltd Main Business Overview &nbsp;13.8.5 Henlius Biopharma Co., Ltd Latest Developments &nbsp;13.9 Jiangsu Hengrui Medicine Co., Ltd &nbsp;13.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information &nbsp;13.9.2 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Jiangsu Hengrui Medicine Co., Ltd Main Business Overview &nbsp;13.9.5 Jiangsu Hengrui Medicine Co., Ltd Latest Developments &nbsp;13.10 Innovent Biologics Co., Ltd &nbsp;13.10.1 Innovent Biologics Co., Ltd Company Information &nbsp;13.10.2 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Innovent Biologics Co., Ltd Main Business Overview &nbsp;13.10.5 Innovent Biologics Co., Ltd Latest Developments &nbsp;13.11 Junshi Biosciences Co., Ltd &nbsp;13.11.1 Junshi Biosciences Co., Ltd Company Information &nbsp;13.11.2 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Junshi Biosciences Co., Ltd Main Business Overview &nbsp;13.11.5 Junshi Biosciences Co., Ltd Latest Developments &nbsp;13.12 BeiGene, Ltd &nbsp;13.12.1 BeiGene, Ltd Company Information &nbsp;13.12.2 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 BeiGene, Ltd Main Business Overview &nbsp;13.12.5 BeiGene, Ltd Latest Developments &nbsp;13.13 Akeso, Inc &nbsp;13.13.1 Akeso, Inc Company Information &nbsp;13.13.2 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications &nbsp;13.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Akeso, Inc Main Business Overview &nbsp;13.13.5 Akeso, Inc Latest Developments 14 Research Findings and Conclusion

Report	Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Growth 2025-2031
Selected License	Multi ID: LPI8361

Buyer Information

Order Summary